Replies to post #16218 on DNAprint Genomics (DNAG)

[chig]

Retired Investor...

Great post.
And that is the crux of the biscuit:

"..if you don't want the man with the vision and the mgt team he feels has the business acumen to help him achieve his goals, what does he[(what do you)] think will be left to grow his investment for him?"

[frogdreaming]

retired investor,

This is a very important point and it raises many questions.

The current relationship between the 'pharma' and the rest of the health industry consists of specific ailments being targeted by a number of independently derived drug solutions in competition with each other. This model has an obvious 'niche' in it for classifiers that help to connect the correct drug to the appropriate individual. As you have mentioned the drug companies are not necessarily interested in supporting such a niche.

On the other hand, a side benefit of the effort to create a classifier also renders other information. Information that can, if discovered early in the development process, actually influence the eventual drug. Perhaps making it more 'universal' in scope or conversely, more finely targeted to a specific trait or population group. While this is a beneficial outcome to the patients and the industry, it does not necessarily have a viable business application. It is obvious that while such a service would be beneficial to a drug manufacturer, if there is no associated classifier there will be no revenue stream for DNAP.

Eventually, it would seem obvious that, given the capability of the platform, if one were able to develop drugs independently there would be obvious revenue ramifications. Until that time, it is difficult to see the path.

We have heard that there are to be a number of clinical trials initiated (or already running) in the near future (did I hear 20?). Given the statements by Frudakis regarding the lack of 'big' money in classifiers, what path is DNAP taking with Moffit in these trials? Are they developing classifiers that don't generate 'big revenue', or are they helping to develop drugs that don't require them? If they assist in the development of drugs that don't need classifiers because they are already targeted to specific populations or are universally applicable to specific diseases, then who 'owns' the drug, and who benefits financially?

It is clear that DNAP sees the future in the development of their own drugs. It is also clear why the development of the previous flagship products such as Statinome have slowed. What is not clear is how the present path will get us to the drug company model and how long it will take. Rmember that a new drug takes many years to develop to marketability.

regards,
frog

[eb0783]

Good post, retired.

After the meeting, Gabriel was showing a few more slides to some of the remaining shareholders. After that, I asked him what the status of Statnome was since I, as well as retired investor (who was standing beside me), had been taking a statin (Zocor and now Lipitor for me) as well as an ACE inhibitor (Accupril).

Obviously I wanted to know, as a stock holder, since we had hoped it would be submitted to the FDA this year but I was also concerned if statins worked for me. OR/and should I expect any liver or other problems or side effects as retired investor was then relating to Gabriel and I. I mean I do three things that are individually hard on my liver: take Statins, occasionally nsaids, and I have my share of wine and cocktails . I would like to be aware/know ahead of time if I’m overloading my liver.

Gabriel said neither it nor any other (Ovanome) of their projects have been put on the back burner or de-emphasized. They are pushing ahead with each of them. That’s when he told retired investor and I we are welcome to join the project and submit a swab to be evaluated.

I’m happy.

Later I’ll post some on the drug development process (not specifics on the actual drugs that are now being supposed) that will be a continuation what retired investor was mentioning as such a concern for that one lady. After the meeting and after the stain discussion with Gabriel, I talked to Gomez about the development “process” in DNAPs future. Later . . .

Paul

[DorseyE]

AMEN!